Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program | Zendy

Leigh Perreault | Zendy; Melanie J. Davies | Zendy; Juan P. Frías | Zendy; Peter Nørkjær Laursen | Zendy; Ildiko Lingvay | Zendy; Sriram Machineni | Zendy; Anette Varbo | Zendy; John Wilding | Zendy; Signe Olrik Rytter Wallenstein | Zendy; Carel W. le Roux | Zendy

Open Access

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Author(s) -

Leigh Perreault,

Melanie J. Davies,

Juan P. Frías,

Peter Nørkjær Laursen,

Ildiko Lingvay,

Sriram Machineni,

Anette Varbo,

John Wilding,

Signe Olrik Rytter Wallenstein,

Carel W. le Roux

Publication year - 2022

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-1785

Subject(s) - prediabetes , medicine , semaglutide , diabetes mellitus , glycemic , endocrinology , carbohydrate metabolism , type 2 diabetes , liraglutide

This analysis of 3,375 adults with overweight/obesity across the Semaglutide Treatment Effect in People with obesity (STEP) 1, 3, and 4 trials evaluated whether more participants with prediabetes had normoglycemia after 68 weeks' treatment with once-weekly semaglutide 2.4 mg plus lifestyle intervention versus placebo and assessed changes in glucose metabolism in participants with prediabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research